Singapore markets close in 6 hours 13 minutes
Straits Times Index
3,356.34 +17.77 (+0.53%) Nikkei
39,779.67 +148.61 (+0.38%) Hang Seng
17,917.34 +198.73 (+1.12%) FTSE 100
8,166.76 +2.64 (+0.03%) Bitcoin USD
62,911.77 -411.07 (-0.65%) CMC Crypto 200
1,344.62 +42.55 (+3.27%)
PCVX Jul 2024 25.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 11:51AM EDT. Market open.
Loading interactive chart…
- Simply Wall St.
We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although...
- GuruFocus.com
Vaxcyte Inc (PCVX) Reports Q1 2024 Earnings: A Detailed Financial and Operational Overview
Consistent with Analyst Projections Amidst Strategic Advancements
- GlobeNewswire
Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
-- VAX-31 Adult Phase 1/2 Study Enrollment Completed; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Following VAX-31 Adult Phase 1/2 Study Readout, Vaxcyte to Advance VAX-24 or VAX-31 to Adult Phase 3 Program -- -- VAX-24 Infant Phase 2 Study Enrollment Completed; Topline Data from Primary Immunization Series Expected by End of First Quarter of 2025, Followed by Topline Data from Booster Dose by End of 2025 -- -- $1.9 Billion in Cash, Cash Equivalen
© 2024 Yahoo. All rights reserved.